Jiangsu Wuzhong plans to invest 156 million yuan in the research and development project of recombinant human endostatin injection, a new biological anticancer drug

Jiangsu Wuzhong issued a fixed increase plan and a draft equity incentive plan at the same time today It plans to increase no more than 45.3 million shares and raise no more than 514 million yuan to no more than 10 specific objects at a price of no less than 11.34 yuan per share It is intended to invest in the pharmaceutical business of the company In terms of fund-raising projects, the company plans to invest 156 million yuan in the research and development project of recombinant human endostatin injection, 46 million yuan in the adjustment and reconstruction project of APIs (Hedong) and preparations (Hexi), 36.7968 million yuan in the three-dimensional warehouse project of pharmaceutical automation, 69 million yuan in the construction project of pharmaceutical marketing network, 106 million yuan in the research and development of pharmaceuticals For the center project, RMB 100 million will be used to supplement the working capital of pharmaceutical business Among the above projects, the company has the independent intellectual property rights of "national first class biological anti-cancer new drug recombinant human endostatin injection research and development project" At present, the third phase clinical trial of the project is steadily advancing in 38 national drug clinical research bases according to the plan According to the announcement, the experimental process initially showed that the drug was safe The future success of phase III clinical trial will provide more beneficial treatment options for the growing number of patients with NSCLC, and it is expected to become a new profit growth point for the company in the future In addition to the fixed increase plan, the company also released the equity incentive draft today The company plans to grant 4.9 million restricted shares to 27 people, including senior management, main management of subsidiaries, middle management and other core technical (backbone) personnel, accounting for 0.7856% of the total 623.7 million shares of the company's current share capital, with the grant price of 6.3 yuan / share The latest closing price of the company is 11.90 yuan / share Restricted shares can be unlocked in three phases The unlocking conditions are: Based on 2014 net profit, the company's net profit growth rate in 2015, 2016 and 2017 is not less than 15%, 30% and 45% respectively.